Researchers developed a compound that could unlock the use of astatine-211 for the treatment of prostate cancer Compounds containing astatine-211 (211At) can be used in targeted radiotherapies for prostate cancer, but deastatination in the body remains a significant hurdle. Now, researchers from Japan have developed a new molecule with a neopentyl glycol structure that effectively prevents deastatination. The proposed structure can be leveraged to accumulate harmful 211At only in tumors while minimizing damage to healthy tissues, paving the way to effective prostate cancer treatment. Image title: In vivo experimental results for a novel compound for targeted alpha therapyImage caption: The figure shows the biodistribution of radioactivity after injecting tumor-bearing mice with [211At]At-NpG-D-PSMA. The results highlight that [211At]At-NpG-D-PSMA accumulates preferentially in tumors while exhibiting low accumulation in the liver and other organs, and therefore holds potential for clinical applications.Image credit: Tomoya Uehara from Chiba UniversityImage license: Original contentUsage restrictions: You are free to share and adapt the material. Attribution is required. … Continue reading Targeted Cancer Therapies: Getting Radioactive Atoms to Accumulate in Tumors